Pieris Pharmaceuticals Inc (NASDAQ: PIRS) stock closed at $23.59 on 4/1/25 after a major decline of -15.7%. Moreover, above average trading volume at 142% of normal accompanied the decline. The stock has declined -15.4% during […]
Ocular Therapeutix Inc (NASDAQ: OCUL) stock suffered a major decline of -10.8% on 4/1/25. The shares closed at $6.54. Moreover, above average trading volume at 138% of normal accompanied the decline. The stock has been […]
Cidara Therapeutics Inc (NASDAQ: CDTX) stock closed at $18.92 on 4/1/25 after a major decline of -12.2%. Moreover, trading volume in this decline was above average at 126% of normal. The stock has declined -19.9% […]
CSP Inc (NASDAQ: CSPI) has recently experienced extremely important negative changes in investment behavior: the stock’s recent price decline challenged its longer term uptrend, and its shorter term price trend turned down. Recent meaningful negative […]
Extremely significant negative changes in Integra LifeSciences Holdings Co (NASDAQ: IART) investment behavior have recently occurred: negative upside/downside volume developed, and its shorter term price trend turned down. Recent meaningful negative changes in fundamentals have […]
Stock Rating Downgrade Reflecting eroding fundamentals and low Appreciation Potential, the Value Trend Rating for Hartford Financial Services Grou (NYSE: HIG) weakened in recent days. HIG’s current Value Trend Rating is C and the prior […]
Stock Rating Upgrade Reflecting improving fundamentals and high Appreciation Potential, the Value Trend Rating for Fox Factory Holding Corp (NASDAQ: FOXF) improved during the last several trading days. FOXF’s current Value Trend Rating is C […]
Stock Rating Downgrade In the last week the Value Trend Rating for Corcept Therapeutics Inc (NASDAQ: CORT) weakened from B to C reflecting eroding fundamentals and low Appreciation Potential. Recent Price Action Corcept Therapeutics Inc […]
Adverum Biotechnologies Inc (NASDAQ: ADVM) stock suffered a major decline of -12.4% on 4/1/25. The shares closed at $3.83. Moreover, unusually high trading volume at 160% of normal accompanied the decline. The stock has been […]
For its fourth fiscal quarter (ending December 31), Ultralife Corp (NASDAQ: ULBI) has reported a -94% decline in E.P.S. from $0.18 a year ago to $0.01 in the current quarter. E.P.S. were $0.38 for the […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research